BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 28949536)

  • 1. Synthesis of Homoverrucosanoid-Derived Esters and Evaluation as MDR Modulators.
    Schäfer A; Köhler SC; Lohe M; Wiese M; Hiersemann M
    J Org Chem; 2017 Oct; 82(19):10504-10522. PubMed ID: 28949536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
    Schmitt SM; Stefan K; Wiese M
    Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):69-79. PubMed ID: 27810353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
    Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
    ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
    J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.
    Köhler SC; Vahdati S; Scholz MS; Wiese M
    Eur J Med Chem; 2018 Feb; 146():483-500. PubMed ID: 29407974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
    Juvale K; Pape VF; Wiese M
    Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
    Krapf MK; Gallus J; Wiese M
    Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.
    Teodori E; Contino M; Riganti C; Bartolucci G; Braconi L; Manetti D; Romanelli MN; Trezza A; Athanasios A; Spiga O; Perrone MG; Giampietro R; Gazzano E; Salerno M; Colabufo NA; Dei S
    Eur J Med Chem; 2019 Nov; 182():111655. PubMed ID: 31494468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
    Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
    J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
    Wong IL; Wang BC; Yuan J; Duan LX; Liu Z; Liu T; Li XM; Hu X; Zhang XY; Jiang T; Wan SB; Chow LM
    J Med Chem; 2015 Jun; 58(11):4529-49. PubMed ID: 25985195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
    Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
    Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
    Yuan J; Wong IL; Jiang T; Wang SW; Liu T; Wen BJ; Chow LM; Wan Sheng B
    Eur J Med Chem; 2012 Aug; 54():413-22. PubMed ID: 22743241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.